SeaStar Medical (NASDAQ:ICU – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of SeaStar Medical in a research report on Thursday, October 15th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $8.00.
Get Our Latest Stock Report on SeaStar Medical
SeaStar Medical Price Performance
Shares of NASDAQ:ICU opened at $0.84 on Friday. SeaStar Medical has a 12 month low of $0.81 and a 12 month high of $5.38. The firm has a market capitalization of $4.46 million, a P/E ratio of -0.23 and a beta of -1.07. The company’s fifty day moving average price is $2.93 and its 200 day moving average price is $3.27.
SeaStar Medical (NASDAQ:ICU – Get Free Report) last released its quarterly earnings data on Wednesday, November 11th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by ($0.08). The company had revenue of $0.64 million during the quarter, compared to analyst estimates of $0.50 million. SeaStar Medical had a negative net margin of 678.24% and a negative return on equity of 261.10%. On average, sell-side analysts anticipate that SeaStar Medical will post -3.66 EPS for the current year.
SeaStar Medical Company Profile
SeaStar Medical Holding Corp. is a medical technology company developing extracorporeal therapies intended to address harmful inflammation in patients with critical illnesses. Its approach uses the Selective Cytopheretic Device (SCD), which processes blood outside the body and is designed to target activated immune cells associated with inflammation. The company’s lead product, QUELIMMUNE, is an SCD-based therapy for certain pediatric patients with acute kidney injury and sepsis or a septic condition who require continuous kidney replacement therapy.
See Also
- Five stocks we like better than SeaStar Medical
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for SeaStar Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaStar Medical and related companies with MarketBeat.com's FREE daily email newsletter.
